Common questions from eye care professionals about amniotic membrane products, clinical use, coding, and coverage.
Coverage varies significantly by product, indication, and payer. Many amniotic membrane products have Medicare coverage for specific ophthalmic indications under HCPCS codes (Q-codes for skin substitutes/tissue products). Commercial payer coverage is contract-dependent, and prior authorization is frequently required. We recommend verifying coverage with individual payers before treatment, and our team can assist with documentation support.
The most commonly used CPT codes include:
In-office self-retained devices typically use 65778 paired with the appropriate HCPCS tissue product code. Always confirm current payer guidelines with your billing team, as coding policies evolve.
Prior authorization requirements vary by payer and product. Medicare Advantage and most commercial plans require prior auth for elective amniotic membrane applications (e.g., DED). Acute/emergent applications (e.g., chemical burns, SJS) may be covered without prior auth under emergency provisions. Blue River Medical can provide clinical documentation templates to support your prior authorization submissions.
Cryopreserved amniotic membrane is maintained at −80°C and retains viable epithelial and stromal cells along with the full growth factor and cytokine profile. It requires frozen storage and has a shorter post-thaw usable window. Dehydrated (lyophilized or air-dried) amniotic membrane is processed for room-temperature storage and has a much longer shelf life (up to 5 years). It does not retain viable cells but preserves the extracellular matrix and most growth factors. For most clinical applications in ophthalmology, dehydrated products are equally effective and more practical for office-based use.
Storage requirements depend on the product format. Dehydrated and lyophilized products are typically stored at room temperature in a clean, dry location — no refrigeration required. Self-retained ring devices are stored at room temperature. Cryopreserved products require an approved −80°C freezer and a documented thaw protocol. Blue River Medical provides storage and handling guidelines for every product we distribute.
Product selection depends on the clinical setting (office vs. OR), indication severity, required application technique, and payer coverage. As a general guide:
Our clinical team is available to help you select the best product for specific cases.
Ideal candidates are patients with moderate-to-severe DED who have failed or had inadequate response to first-line therapies (artificial tears, cyclosporine, lifitegrast, punctal occlusion). Clinically, patients with an OSDI score above 33 and corneal staining grade 2+ on the Oxford scale are typically appropriate. Patients with autoimmune-related DED (Sjögren's, GvHD) often respond particularly well.
Most DED patients undergo an initial series of 2–3 treatment cycles (each cycle = one 5–7 day device wear). The duration of symptomatic relief varies — many patients experience benefit for 4–12 weeks after a completed series, while others require ongoing quarterly maintenance. Response should be assessed with objective metrics (staining, TBUT) as well as patient-reported symptoms.
Absolute contraindications are rare. Active ocular infection (bacterial, viral, or fungal) in the area of application is a contraindication until the infection is adequately treated. Known sensitivity to human tissue products or preservatives used in specific formulations should be considered. Self-retained devices may be poorly tolerated in patients with very narrow palpebral fissures. As with all tissue products, practitioners should review individual product IFUs for contraindications.
All FDA-regulated amniotic membrane products are sourced from consenting donors (mothers undergoing scheduled C-sections) through accredited tissue banks in compliance with FDA 21 CFR Part 1271 and AATB standards. Donors undergo rigorous infectious disease screening. Blue River Medical partners exclusively with manufacturers who follow these ethical sourcing and processing standards.
Yes. Amniotic membrane has been used safely in pediatric patients — particularly in acute SJS, chemical burns, and congenital ocular surface conditions such as aniridia-related keratopathy. Application technique may need modification for patient cooperation, and in younger children, examination under anesthesia (EUA) may be required for placement.